Back to News
Market Impact: 0.38
Amneal Gains FDA Approval For Generic Lanreotide Injection; Launches Drug Immediately
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Amneal Pharmaceuticals received FDA approval for its Lanreotide injection, a generic version of SOMATULINE Depot. The approval expands Amneal's generic-drug portfolio and creates a potential new revenue opportunity in the specialty injectable market.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
Ticker Sentiment
AMRX0.78
More News
- Apple's quarter is not perfect. But with enough to like, we raised our price target
- Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- California’s Bay Area debates data centres ahead of US midterm elections
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- ‘Fastest entertainment property in history’: GTA VI arrives to test a thin November box office